

Christos S Karapetis

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8014876/christos-s-karapetis-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83

papers

6,439

citations

22

h-index

80

g-index

90

ext. papers

7,272

ext. citations

6.2

avg, IF

5.1

L-index

#	Paper	IF	Citations
83	K-ras mutations and benefit from cetuximab in advanced colorectal cancer. <i>New England Journal of Medicine</i> , 2008 , 359, 1757-65	59.2	2912
82	Cetuximab for the treatment of colorectal cancer. <i>New England Journal of Medicine</i> , 2007 , 357, 2040-8	59.2	1587
81	Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 1812-20	27.4	580
80	Colorectal cancer: Metastases to a single organ. <i>World Journal of Gastroenterology</i> , 2015 , 21, 11767-76	5.6	147
79	PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. <i>Clinical Cancer Research</i> , 2014 , 20, 744-53	12.9	117
78	Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 1182-92	9.7	104
77	Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1822-8	2.2	95
76	Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1440-1446	8.9	53
75	The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. <i>Acta Oncologica</i> , 2018 , 57, 1438-1444	3.2	48
74	Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 87-93	3.8	43
73	Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2258-64	2.2	41
72	The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer. <i>Frontiers in Genetics</i> , 2019 , 10, 1118	4.5	39
71	Practical Considerations for Treating Patients With Cancer in the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2020 , 16, 467-482	2.3	37
70	A population-based study of metastatic colorectal cancer in individuals aged ≥80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer. <i>Cancer</i> , 2013 , 119, 722-8	6.4	33
69	Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. <i>European Urology</i> , 2020 , 78, 540-543	10.2	33
68	Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 32-6	3.8	27
67	Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. <i>European Journal of Cancer</i> , 2016 , 55, 122-30	7.5	26

66	Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial. <i>Archives of Pathology and Laboratory Medicine</i> , 2013 , 137, 820-7	5	26
65	Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. <i>International Journal of Cancer</i> , 2021 , 148, 1014-1026	7.5	26
64	Current opinion on optimal treatment for colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 597-611	3.5	24
63	Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 2435-44	12.9	24
62	Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. <i>Clinical Cancer Research</i> , 2020 , 26, 5487-5493	12.9	23
61	RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 95-103	3.8	22
60	Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1741-1750	4.9	21
59	Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). <i>EBioMedicine</i> , 2019 , 50, 433-441	8.8	21
58	Online information and support needs of women with advanced breast cancer: a qualitative analysis. <i>Supportive Care in Cancer</i> , 2018 , 26, 3489-3496	3.9	20
57	The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers. <i>Frontiers in Oncology</i> , 2018 , 8, 275	5.3	19
56	Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. <i>PLoS ONE</i> , 2015 , 10, e0135599	3.7	19
55	Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. <i>European Journal of Cancer</i> , 2012 , 48, 1293-8	7.5	19
54	Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab. <i>Clinical Cancer Research</i> , 2020 , 26, 3280-3286	12.9	18
53	Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying. <i>Internal Medicine Journal</i> , 2018 , 48, 774-779	1.6	16
52	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. <i>PLoS Medicine</i> , 2021 , 18, e1003620	11.6	16
51	Personalized treatment for advanced colorectal cancer: KRAS and beyond. <i>Cancer Management and Research</i> , 2013 , 5, 387-400	3.6	15
50	Identification of microRNA Biomarkers of Response to Neoadjuvant Chemoradiotherapy in Esophageal Adenocarcinoma Using Next Generation Sequencing. <i>Annals of Surgical Oncology</i> , 2018 , 25, 2731-2738	3.1	12
49	Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. <i>Cancer Medicine</i> , 2015 , 4, 1461-71	4.8	12

48	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 1477-93	3.5	12
47	Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3616-3622	3.1	11
46	Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. <i>British Journal of Cancer</i> , 2021 ,	8.7	8
45	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. <i>Clinical Colorectal Cancer</i> , 2010 , 9, 8-14	3.8	7
44	Use of guideline-recommended adjuvant therapies and survival outcomes for people with colorectal cancer at tertiary referral hospitals in South Australia. <i>Journal of Evaluation in Clinical Practice</i> , 2018 , 24, 135-144	2.5	7
43	Usefulness of Aquaporin 1 as a Prognostic Marker in a Prospective Cohort of Malignant Mesotheliomas. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	7
42	Reply: Comment on Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer <i>British Journal of Cancer</i> , 2015 , 113, 1635	8.7	6
41	Pre-treatment serum lactate dehydrogenase as a biomarker in small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, e64-e70	1.9	6
40	Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, 313-319	3.8	6
39	Equivalence of outcomes for rural and metropolitan patients with metastatic colorectal cancer in South Australia. <i>Medical Journal of Australia</i> , 2014 , 201, 462-6	4	6
38	Survival and late toxicities following concurrent chemo-radiotherapy for locally advanced stage III non-small cell lung cancer: findings of a 10-year Australian single centre experience with long term clinical follow up. <i>Journal of Thoracic Disease</i> , 2019 , 11, 4241-4248	2.6	6
37	Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune-related adverse events after immune checkpoint inhibitor therapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020 , 16, e139-e145	1.9	6
36	Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. <i>Current Problems in Cancer</i> , 2021 , 45, 100637	2.3	6
35	Expanded Low Allele Frequency and V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 52-59	12.9	6
34	Cardiotoxicity after cancer treatment: a process map of the patient treatment journey. <i>Cardio-Oncology</i> , 2019 , 5, 14	2.8	5
33	BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?. <i>Molecular Diagnosis and Therapy</i> , 2016 , 20, 75-82	4.5	5
32	Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 3838-3844	12.9	5
31	Perceptions of cancer of unknown primary site: a national survey of Australian medical oncologists. <i>Internal Medicine Journal</i> , 2017 , 47, 408-414	1.6	4

30	Female breast cancer management and survival: The experience of major public hospitals in South Australia over 3 decades-trends by age and in the elderly. <i>Journal of Evaluation in Clinical Practice</i> , 2017 , 23, 1433-1443	2.5	4
29	Pre-diagnostic colonoscopies reduce cancer mortality - results from linked population-based data in South Australia. <i>BMC Cancer</i> , 2019 , 19, 856	4.8	4
28	Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab. <i>Targeted Oncology</i> , 2019 , 14, 743-748	5	4
27	Outcomes of Older Patients (≥70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e140-e149	3.8	4
26	Internet use and preferences among women living with advanced breast cancer. <i>Breast Journal</i> , 2019 , 25, 290-295	1.2	3
25	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 251-270	3.5	3
24	Survival Outcomes for Patients With Indeterminate 18FDG-PET Scan for Extrahepatic Disease Before Liver Resection for Metastatic Colorectal Cancer: A Retrospective Cohort Study Using a Prospectively Maintained Database to Analyze Survival Outcomes for Patients With Indeterminate	7.8	3
23	Extrahepatic Disease on 18FDG-PET Scan Before Liver Resection for Metastatic Colorectal Cancer. A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010 , 6, 298-305	1.9	3
22	Efficacy of atezolizumab in patients with advanced non-small cell lung cancer receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomised control trials.: Proton pump inhibitors, antibiotics, and immunotherapies.. <i>Journal of Thoracic Oncology</i> , 2022 ,	8.9	3
21	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 557-71	3.5	2
20	Australia and New Zealand's responsibilities in improving oncology services in the Asia-Pacific: A call to action. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021 ,	1.9	2
19	Female breast cancer treatment and survival in South Australia: Results from linked health data. <i>European Journal of Cancer Care</i> , 2021 , 30, e13451	2.4	2
18	Risk Factors for Severe Diarrhea with an Afatinib Treatment of Non-Small Cell Lung Cancer: A Pooled Analysis of Clinical Trials. <i>Cancers</i> , 2018 , 10,	6.6	2
17	Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e208	8.9	1
16	Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer. <i>Colorectal Cancer</i> , 2012 , 1, 137-148	0.8	1
15	A collaborative approach to meeting oncology challenges in island communities in the Asia-Pacific region. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021 , 65, 418-423	1.7	1
14	Serum vitamin D decreases during chemotherapy: an Australian prospective cohort study. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2018 , 27, 962-967	1	1
13	Investigating the breast cancer screening-treatment-mortality pathway of women diagnosed with invasive breast cancer: Results from linked health data. <i>European Journal of Cancer Care</i> , 2021 , 31, e135394	2.4	0

12	Dose modification for haematological toxicity: a survey of Australian medical oncologists. <i>Internal Medicine Journal</i> , 2020 , 50, 1338-1343	1.6	o
11	Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites. <i>European Journal of Clinical Pharmacology</i> , 2021 , 1	2.8	o
10	A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.. <i>BMC Cancer</i> , 2022 , 22, 222	4.8	o
9	Author's Reply. <i>Journal of Thoracic Oncology</i> , 2019 , 14, e210	8.9	
8	Authors' Reply to Yu: "Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry". <i>Targeted Oncology</i> , 2019 , 14, 367-368	5	
7	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2015 , 15, 1033-48	3.8	
6	Response to: "Consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients With Colorectal Liver Metastases". <i>Annals of Surgery</i> , 2018 , 268, e9-e10	7.8	
5	Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non-small-cell lung cancer: Is thrombocytopenia predictable?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2009 , 5, 24-31	1.9	
4	Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 88, 39-52	3.5	
3	Second-line FOLFOX chemotherapy for advanced biliary tract cancer. <i>Lancet Oncology</i> , 2021 , 22, e286	21.7	
2	Acanthosis Palmaris: A Rare Paraneoplastic Manifestation of Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2018 , 14, 331-332	3.1	
1	Author reply. <i>Internal Medicine Journal</i> , 2018 , 48, 1415-1416	1.6	